Chapter 1. Executive summary

1.1. Market scope and segmentation
1.2. Key questions answered
1.3. Executive summary

Chapter 2. Global conjugate vaccine market – overview

2.1. Market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), geography-wise market revenue (USD Bn), and market attractiveness analysis
2.2. Market drivers
2.3. Market trends
2.4. Market challenges
2.5. Value chain analysis
2.6. Porter’s five forces analysis
2.7. Segmentation based on disease indication (pneumococcal conugate vaccine (PCV), haemophilus influenzae type B (Hib) conjugate vaccine, diptheria, tetanus toxoids and pertussis (DTP) conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations
2.8. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 3. North America conjugate vaccine market

3.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations
3.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations
3.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 4. Europe conjugate vaccine market

4.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations
4.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations
4.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 5. Asia-Pacific conjugate vaccine market

5.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations
5.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations
5.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 6. Latin America conjugate vaccine market

6.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations
6.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations
6.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 7. The Middle East and Africa conjugate vaccine market

7.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations
7.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations
7.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 8. Competitive landscape

8.1. GlaxoSmithKline
8.1.a. Company snapshot
8.1.b. Products/services
8.1.c. Major initiatives/highlights
8.1.d. Growth strategy
8.1.e. Geographical presence
8.1.f. Key numbers
Note: Similar information areas will be covered for the remaining competitors:
8.2. Pfizer Inc.
8.3. Merck & Co.
8.4. Novartis
8.5. Sanofi Pasteur
8.6. CSL Limited
8.7. Bharat Biotech International
8.8. Biological E Limited
8.9. Serum Institute of India

Chapter 9. Conclusion
9.1. Future outlook

Appendix

1. List of tables

2. Research methodology

3. Assumptions

4. About Netscribes Inc.